These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 19470707)

  • 1. A unique rodent model of cardiometabolic risk associated with the metabolic syndrome and polycystic ovary syndrome.
    Shi D; Dyck MK; Uwiera RR; Russell JC; Proctor SD; Vine DF
    Endocrinology; 2009 Sep; 150(9):4425-36. PubMed ID: 19470707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiometabolic and reproductive benefits of early dietary energy restriction and voluntary exercise in an obese PCOS-prone rodent model.
    Diane A; Kupreeva M; Borthwick F; Proctor SD; Pierce WD; Vine DF
    J Endocrinol; 2015 Sep; 226(3):193-206. PubMed ID: 26187902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
    Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
    Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycystic ovary syndrome and the metabolic syndrome.
    Weerakiet S
    J Med Assoc Thai; 2004 Oct; 87 Suppl 3():S189-93. PubMed ID: 21213522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
    Moghetti P; Tosi F; Bonin C; Di Sarra D; Fiers T; Kaufman JM; Giagulli VA; Signori C; Zambotti F; Dall'Alda M; Spiazzi G; Zanolin ME; Bonora E
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome.
    Mannerås L; Cajander S; Holmäng A; Seleskovic Z; Lystig T; Lönn M; Stener-Victorin E
    Endocrinology; 2007 Aug; 148(8):3781-91. PubMed ID: 17495003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.
    Kupreeva M; Diane A; Lehner R; Watts R; Ghosh M; Proctor S; Vine D
    Am J Physiol Endocrinol Metab; 2019 Jan; 316(1):E16-E33. PubMed ID: 30153063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-fat diet induces significant metabolic disorders in a mouse model of polycystic ovary syndrome.
    Lai H; Jia X; Yu Q; Zhang C; Qiao J; Guan Y; Kang J
    Biol Reprod; 2014 Nov; 91(5):127. PubMed ID: 25100714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rodent models for human polycystic ovary syndrome.
    Walters KA; Allan CM; Handelsman DJ
    Biol Reprod; 2012 May; 86(5):149, 1-12. PubMed ID: 22337333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of dehydroepiandrosterone-treated rats is not a good animal model for the study of metabolic abnormalities in polycystic ovary syndrome.
    Seow KM; Ting CH; Huang SW; Ho LT; Juan CC
    Taiwan J Obstet Gynecol; 2018 Oct; 57(5):696-704. PubMed ID: 30342654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early metabolic derangements in daughters of women with polycystic ovary syndrome.
    Sir-Petermann T; Maliqueo M; Codner E; Echiburú B; Crisosto N; Pérez V; Pérez-Bravo F; Cassorla F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4637-42. PubMed ID: 17848407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
    Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
    Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic ovary syndrome in the Indian Subcontinent.
    Allahbadia GN; Merchant R
    Semin Reprod Med; 2008 Jan; 26(1):22-34. PubMed ID: 18181079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk.
    Amato MC; Verghi M; Galluzzo A; Giordano C
    Hum Reprod; 2011 Jun; 26(6):1486-94. PubMed ID: 21447694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome.
    Gateva AT; Kamenov ZA
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):161-6. PubMed ID: 22727921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome.
    Lord J; Thomas R; Fox B; Acharya U; Wilkin T
    BJOG; 2006 Oct; 113(10):1203-9. PubMed ID: 16753044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
    Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
    Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.